These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 34779643)

  • 1. Research progress on the treatment of advanced prostate cancer with Olaparib.
    Su YX; Yu CF; Xue P; Li LL; Xiao KM; Chu XL; Zhu SJ
    Neoplasma; 2021 Nov; 68(6):1132-1138. PubMed ID: 34779643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
    McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
    Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    Zhu Q; Chen J; Liu H; Zhao J; Xu C; Sun G; Zeng H
    BMC Cancer; 2024 Jun; 24(1):706. PubMed ID: 38851712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
    Dariane C; Timsit MO
    Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
    Adashek JJ; Jain RK; Zhang J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
    Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
    Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Talazoparib for the treatment of prostate cancer.
    Narang A; Hage Chehade C; Ozay ZI; Nordblad B; Swami U; Agarwal N
    Expert Opin Pharmacother; 2024 Sep; 25(13):1717-1727. PubMed ID: 39210559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
    Marshall CH; Teply BA; Lu J; Oliveira L; Wang H; Mao SS; Kelly WK; Paller CJ; Markowski MC; Denmeade SR; King S; Sullivan R; Davicioni E; Proudfoot JA; Eisenberger MA; Carducci MA; Lotan TL; Antonarakis ES
    JAMA Oncol; 2024 Oct; 10(10):1400-1408. PubMed ID: 39172479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should We "PROpel" Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?
    VanderWeele DJ; Hussain M
    NEJM Evid; 2022 Sep; 1(9):EVIDe2200154. PubMed ID: 38319811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
    Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
    BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    VanderWeele DJ; Hussain M
    Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.
    LeVee A; Lin CY; Posadas E; Figlin R; Bhowmick NA; Di Vizio D; Ellis L; Rosser CJ; Freeman MR; Theodorescu D; Freedland SJ; Gong J
    Onco Targets Ther; 2021; 14():4819-4832. PubMed ID: 34552338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    Bieńkowski M; Tomasik B; Braun M; Jassem J
    Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.